1. Clinically there was no evidence of portal hypertension.

2. Conversely, there was no significant association with portal hypertension.

3. Our patient thus failed to show evidence of portal hypertension.

4. Discussion Portal hypertension usually complicates the evolution of chronic liver diseases.

5. However spontaneous portal vein thrombus may occur in portal hypertension and the infusion of vasopressin may also play a part.

6. Portal hypertension with stasis and pooling of blood in the reticuloendothelial meshwork may interfere with this process.

6. try its best to collect and create good sentences.

7. Materials and Methods: 90 patients with portal hypertension, and 86 normal subjects had their blood flow parameters in inferior epigastric artery and veins assessed by 2D and CDFI ultrasound.

8. The features cirrhotic portal hypertension were within liver, larger in spleen and widen in portal vein.

9. One of the most common findings with portal hypertension is splenomegaly as seen here.

10. Purpose:To study the value of DSA in treating portal hypertension by subtotal splenectomy with retroperitoneal splenic trans position and devascularization.

11. Chronic constipation, chronic diarrhea, pregnancy, and portal hypertension enhance hemorrhoid formation.

12. Patients described in published works with portopulmonary hypertension have all had clinically obvious portal hypertension.

13. Over half of the patients exhibit clinical signs associated with portal hypertension, such as ascites and hepatorenal syndrome.

14. Decisions regarding appropriate organ transplantation may depend on whether pulmonary hypertension is primary or secondary to portal hypertension.

15. Complete or partial occlusion of the portal vein is a common cause of portal hypertension in childhood.

16. Recently Hadengue etal reported a higher prevalence of 2% in 507 patients with portal hypertension.

17. Many treatments have evolved over the last 30 years for controlling upper gastrointestinal haemorrhage in patients with cirrhosis and portal hypertension.

18. Gastric varices Gastric varices are not uncommon in cirrhotic patients with portal hypertension.

19. Treatment was discontinued when patients developed evidence of cirrhosis or portal hypertension.

20. As mentioned previously, all cases of portopulmonary hypertension reported have had obvious portal hypertension.

21. Pericardial devascularization plus endoscopic variceal ligation(EVL) was applied in our hospital as a new union devascularization therapy for 66 cirrhotic portal hypertension patients since 1993.

22. Objective To study the hemodynamic effects of thalidomide on experimental portal hypertension rats and its relation with tumor necrosis factor (TNF).

23. Objective : To investigate the clinical significance of paraumbilical vein ( PUV ) patefaction extent of portal hypertension.

24. Objective To study the cause, treatment and prevention of gastric rupture after pericardial devascularization plus splenectomy in the treatment of portal hypertension.

25. Prof. Sarin: Bleeding from gastric varices is a major cause of death in portal hypertension.

26. The authors studied the pre and post-operative portography via gastroepiploic vein catheterization performed in 8 patients with portal hypertension of various degrees.

27. Methods Liceratures of overseas main studies in hyperdynamic circulatory syndrome of portal hypertension in recent 10 years were reviewed.

28. Objective:To evaluate the clinical value of spiral CT during arterial portography (SCTAP) in judgment of cirrhosis and portal hypertension.

29. The limited side-to-side portal-caval shunt with a limitary ring attached is the first-choice surgical procedure to treat the portal hypertension in our department.

30. Objective: To probe the effect of application of artificial blood vessel with ring in port acaval shunt for portal hypertension.

31. Objective : To investigate the clinical value of liver vascular index ( LVI ) in cirrhosis and portal hypertension.

32. Conclusion Distal splenocaval shunt is suitable for portal hypertension patients with hepatopetal portal flow.

33. Objective : To explore and analyse ther eason preventive measure of portal hypertension gastrobrosis after devascula rization.

34. Portal hypertension, splanchnic vasodilatation, liver insufficiency, and cardiovascular dysfunction are major pathophysiological hallmarks.

35. So we concluded that the endogenous cannabinoids may participate in liver fibrogenesis and portal hypertension in mouse liver fibrosis infected with S. japonicum.

36. The maintenance of portal hypertension in hyperkinetic circulatory state is closely related to nitric oxide (NO) formation.

37. Objective To determine the mechanism of nitric oxide synthase(NOS) and prostacyclin(PGI2) acting on splanchnic hyperdynamic circulation of portal hypertension(PHT).

38. The diagnosis of hepatic hydrothorax should be suspected in a patient with established cirrhosis and portal hypertension, presenting with a unilateral pleural effusion,[http:///portal hypertension.html] most commonly right-sided.

39. The parameters above measured in different groups including control group, portal hypertension group, choledochus obstruction group, and malignant tumor group were compared.

40. Prof. Sanyal: There are actually a lot of studies in the area of portal hypertension.

41. Objective To approach the clinical characteristic and the selection of the treatment of prehepatic portal hypertension.

42. Hepatoportal sclerosis ( HPS ) is one of the causes of non cirrhotic portal hypertension.

43. Conclusion It is an ideal operation method in the treatment of hepatocirrhosis and portal hypertension.

44. Hypertension and renal insufficiency and portal hypertension are common clinical manifestations.

45. Conclusion: Dectecting serum NO can by used as an index for predicting cirrhotic portal hypertension. Serum NO plays an important role in hyperdynamic circulation of cirrhotic patients.

46. Thy Dopplex technique provides feasible method for the decision of pituitrin treatment in portal hypertension.

47. Objective To explore the cause of disease, clinical characteristic and diagnosis and treatment of pancreatogenic segmental portal hypertension.

48. Aims:To evaluate the role of increased portal pressure and portosystemic shunting in elevated level of prostacyclin(PGI2) in portal hypertension.

49. Objective To discuss the effect of the therapy of the portal hypertension complicated with thoracic esophageal varices and bleeding by the esophagogastric devascularization.

50. Objective : To investigate the diagnosis and treatment of pancreatic sinistral portal hypertension ( PSPH ).

51. The advanced patients often possess severe jaundice, severe liver dysfunction, biliary cirrhosis, portal hypertension.

52. Conclusion SAAG is valuable to differentiate ascitic fluid of portal hypertension from that of non-portal hypertension, and is superior to the exudate–transudate classification.

53. Conclusion Hyperdynamic circulatory syndrome contribute to the maintenance and aggregation of portal hypertension.

54. Chronic portal hypertension may lead to development of collateral circulation , which is manifested as caput medusa in the region of the umbilicus and epigastrium.

55. Bankground and study aim:portal hypertension is common in Egypt as a sequela to the high prevalence of hepatitis C virus and bilharziasis.

56. Conclusion Potal anticoagulation therapy is the effective in preventing portal thrombosis after porta -azygous devascularization for portal hypertension.

57. Abdominal ultrasound examinations showed cirrhosis, portal hypertension, splenomegaly. Echocardiogram showed left ventricular myohypertrophia, mild mitral and tricuspid valve insufficiency.

58. It suggested that congenital hepatic fibrosis should be suspected in patients with symptoms or signs of portal hypertension; but could also masquerade in as recurrent fever without hematemesis .

59. Objective To explore the risk factors of portal system thrombosis after splenectomy in patient with portal hypertension.

60. One of the most common causes for splenomegaly is portal hypertension with cirrhosis of the liver.

61. In general, hepatic synthetic function is preserved and treatment is at relief of the portal hypertension.

62. Conclusion SAAG is valuable to differentiate ascitic fluid of portal hypertension from that of non-portal hypertension, and is superior to the exudates -transudate classification.

63. Objective:To evaluate the value of multi-detector row spiral CT portography(MDCTP) in demonstrating portal system and its collaterals in portal hypertension.

64. Conclusion:Release-controlled nifedipine is healed for hepatogenic ulcer, and can reduce portal hypertension distinctly.

65. Objective : To evaluate the situation of combined operation in preventive operation for portal hypertension ( PHT ).

66. Further work - up showed portal hypertension with esophageal varices.

67. Objective To evaluate the typic technique of pericardial devascularization and its effect on upper digestive tract bleeding due to portal hypertension.

68. The therapeutic management of hepatic portal hypertension in patients with cirrhosis is still a challenge.

69. Objective To evaluate the diagnostic value in liver cirrhosis with portal hypertension between ultrasound and computer tomography (CT).

70. Splenectomy is a choice for pancreatogenic portal hypertension derived from the tail of pancreas.

71. Objective:To investigate the clinical value of liver vascular index(LVI) in patients with liver cirrhosis and portal hypertension.

72. Objective : To explore the method of treatment for cirrhosis associated portal hypertension and hepatogenic diabetes.

73. This study reports 5 cases of surgically treated suprahepatic portal hypertension.

74. Portacaval shunts have been performed for recent variceal hemorrhage in cirrhotic patients without the physician suspecting that a hepatoma was responsible for the portal hypertension.

75. Objective:To explore the relationship between the plasma level of NO and the hyperdynamic circulation of cirrhotic patients with portal hypertension.

76. Methods :The clinical data of 46 cases of cirrhosis with portal hypertension and hepatogenic diabetes treated in recent 10-year period were retrospectively analyzed.

77. Objective To study the therapeutic effect of stomach coronary vein TH glue embolism plus lienectomy in the treatment of portal hypertension.

78. Objective To explore the reasons for postoperative complication of gastric necrosis and gastrobrosis in patients with portal hypertension after devascularization and its treatment.

79. There was no significant deviation among different MDCT scores that other indexes of portal hypertension,[http:///portal hypertension.html] except the diameter of the left gastric vein.

80. Conclusion The constellation of clinical findings of portal hypertension, cutaneous spider nevi and clubbing finger is strongly suggestive of HPS.

81. Objective To study the diagnosis and treatment of regional portal hypertension.

82. Objective : To study clinical effect of splenectomy plus pericardial revascularization in portal hypertension.

83. Therefore, DUS is the method of choice to study hemodynamics of portal hypertension and should be used routinely before and after operation.

84. Conclusion Continous instillation of somatostatin via peripheral vein can decrease the portal venous pressure portal hypertension.

85. Objectives To explore and analyse the reason and prevention measure of portal hypertension bleeding after devascularization.

86. To observe and measure portal vein and varicose vein in esophagus and gastric fundus of the portal hypertension by CT, try to find a marker to predict the upper gastrointestinal hemorrhage.

87. Portal hypertension and metabolic diseases, such as Wilson's disease and hemochromatosis, can also cause significant liver problems.

88. Objective : To investigate the hypercoagulation of the rats with cirrhosis and portal hypertension after splenectomy.

89. Gastric varices in patients with portal hypertension should be correctly identified.

90. Conclusions: Hepatogenic ulcer was difficult to treat. It hemorrhage rate was much higher due to portal hypertension and small dose of prapanolol is healed for hepatogenic ulcer.

91. Objective To investigate the value of multi-detector row spiral CT (MDCT) portography in assessing the portosystemic collateral vessels in liver cirrhosis with portal hypertension.

92. Conclusion NO plays an important role in hyperdynamic circulation in cirrhotic portal hypertension.